natgillin/translations-raw huggingface dataset:
A compound of formula I or an enantiomer, diastereomer, tautomer or isotopic variant thereof; 
Spoj formule I [image] ili njegov enantiomer, dijastereomer, tautomer ili izotopska varijanta;
or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; 
i R4, zajedno sa atomima za koje su vezani, obrazuje 6-člani aril prsten ili 5-11 i 6-člani heteroaril prsten;
or a pharmaceutically acceptable salt or solvate thereof; wherein: ring A is a heteroaryl ring selected from the group consisting of furanyl, thiazolyl, imidazothiazolyl and pyrazinyl; 
ili njegova farmaceutski prihvatljiva sol ili solvat; naznačen time da prsten A je heteroaril prsten odabran iz skupine koju čine furanil, tiazolil, imidazotiazolil i pirazinil;
or R3 and R4, together with the atoms to which they are attached, form a 6-membered aryl ring or a 5- or 6-membered heteroaryl ring; 
ili R3 i R4, zajedno sa atomima za koje su vezani, obrazuje 6-člani aril prsten ili 5-ili 6-člani heteroaril prsten;
The compound for use of claim 23, wherein the disease, disorder, or medical condition is a mood disorder, a post-traumatic stress disorder, a panic disorder, an attention deficit disorder, cognitive deficiencies, or substance abuse. 
Spoj za uporabu prema zahtjevu 23, naznačen time da bolest, poremećaj ili medicinsko stanje je poremećaj raspoloženja, posttraumatski poremećaj, panični poremećaj, poremećaj nedostatka pažnje, kognitivna deficijencija ili zloupotreba tvari.
The compound for use of claim 23, wherein the disease, disorder, or medical condition is a sleep disorder. 
Spoj za uporabu prema zahtjevu 23, naznačen time da bolest, poremećaj ili medicinsko stanje je poremećaj spavanja.
The compound for use of claim 25, wherein the sleep disorder is a sleep-wake transition disorder, insomnia, restless legs syndrome, jet-lag, disturbed sleep, or a sleep disorder secondary to neurological disorders. 
Spoj za uporabu prema zahtjevu 25, naznačen time da je poremećaj spavanja poremećaj prelaska iz sna u budnost, nesanica, sindrom nemirnih nogu, jet-lag, poremećaj spavanja, ili sekundarni poremećaj spavanja u vezi s neurološkim poremećajima.
The compound for use of claim 23, wherein the disease, disorder, or medical condition is a metabolic disorder. 
Spoj za uporabu prema zahtjevu 23, naznačen time daje bolest, poremećaj ili medicinsko stanje metabolički poremećaj.
The compound for use of claim 27, wherein the metabolic disorder is overweight, obesity, insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins, or osteoarthritis. 
Spoj za uporabu prema zahtjevu 27, naznačen time da je metabolički poremećaj prekomjerna težina, gojaznost, otpornost na inzulin, dijabetes tipa II, hiperlipidemija, žučni kamenac, angina, hipertenzija, kratak dah, tahikardija, neplodnost, apneja u snu, bol u leđima i zglobovima, proširene vene, ili osteoartritis.
The compound for use of claim 23, wherein the disease, disorder, or medical condition is a neurological disorder. 
Spoj za uporabu prema zahtjevu 23, naznačen time da je bolest, poremećaj ili medicinsko stanje neurološki poremećaj.
The compound for use of claim 29, wherein the neurological disorder is Parkinson's disease, Alzheimer's disease, Tourette's syndrome, catatonia, anxiety, delirium, or dementia. 
Spoj za uporabu prema zahtjevu 29, naznačen time da je neurološki poremećaj Parkinsonova bolest, Alzheimerova bolest, Touretteov sindrom, katatonija, anksioznost, delirij ili demencija.
subjecting the primary suspension to first pulverization to form a secondary suspension; and 
podvrgavanje primarne suspenzije prvom pretvaranju u prah da nastane druga suspenzija; i
subjecting the secondary suspension to second pulverization to form a final suspension, wherein in the first pulverization of step (b), the secondary suspension is formed by pulverizing the primary suspension using a high shear pulverizing machine or a dispersion machine that applies shear force to a material to be processed, and in the second pulverization of step (c), the final suspension is formed by pulverizing the secondary suspension using a high-pressure homogenizer. 
podvrgavanje sekundarne suspenzije drugom pretvaranju u prah da nastane konačna suspenzija, naznačen time da u prvom pretvaranju u prah iz koraka (b), sekundarna suspenzija nastaje pretvaranjem u prah primarne suspenzije korištenjem stroja za pulverizaciju s visokim smicanjem ili disperzijskog stroja koji primjenjuje silu smicanja na materijal koji se obrađuje, te u drugom pretvaranju u prah iz koraka (c), konačna suspenzija nastaje pretvaranjem u prah sekundarne suspenzije korištenjem visokotlačnog homogenizatora.
subjecting the secondary suspension to second pulverization to form a final suspension, wherein in the first pulverization of step (b), the secondary suspension is formed by pulverizing the primary suspension using a high-pressure homogenizer at a pulverization pressure of 50 to 200 bar, and in the second pulverization of step (c), the final suspension is formed by pulverizing the secondary suspension using a high-pressure homogenizer at a pulverization pressure of 200 to 1000 bar, wherein the difference between the pulverization pressure in step (b) and the pulverization pressure in step (c) is 100 to 900 bar. 
podvrgavanje sekundarne suspenzije drugom pretvaranju u prah da nastane konačna suspenzija, naznačen time da u prvom pretvaranju u prah iz koraka (b), sekundarna suspenzija nastaje pretvaranjem u prah primarne suspenzije korištenjem visokotlačnog homogenizatora kod tlaka usitnjavanja od 50 do 200 bar, te u drugom pretvaranju u prah iz koraka (c), konačna suspenzija nastaje pretvaranjem u prah sekundarne suspenzije korištenjem visokotlačnog homogenizatora kod tlaka usitnjavanja od 200 do 1000 bar, pri čemu je razlika između tlaka usitnjavanja u koraku (b) i tlaka usitnjavanja u koraku (c) 100 do 900 bar.
The method according to claim 4, wherein in step (b), the pulverization pressure of the high-pressure homogenizer is in the range of 50 to 200 bar, and in step (c), the pulverization is carried out plural times and the pulverization pressure is raised stepwise within the range of 200 to 1000 bar. 
Postupak prema zahtjevu 4, naznačen time da u koraku (b), tlak usitnjavanja visokotlačnog homogenizatora je u rasponu od 50 do 200 bar, a u koraku (c), pretvaranje u prah se provodi više puta i tlak usitnjavanja se podiže postupno u rasponu od 200 do 1000 bar.
The method according to claim 1 or claim 4, wherein the vehicle contains at least one suspending agent selected from the group consisting of carboxymethyl cellulose, carboxymethyl celllose salts, hydroxypropyl cellulose, hydroxypropylethyl cellulose, hydroxypropylmethyl cellulose and polyvinyl pyrrolidone. 
Postupak prema zahtjevu 1 ili zahtjevu 4, naznačen time da nosač sadrži najmanje jedno suspenzijsko sredstvo odabrano iz skupine koju čine karboksimetil celuloza, soli karboksimetil celuloze, hidroksipropil celuloza, hidroksipropiletil celuloza, hidroksipropilmetil celuloza i polivinil pirolidon.
combining sterile bulk aripiprazole with a volume mean particle size of 200 µm to 400 µm as measured by LLS, and a sterile vehicle to form a sterile primary suspension; 
miješanje sterilnog rasutog aripiprazola s volumnom srednjom veličinom čestica od 200 µm do 400 µm mjereno pomoću LLS, i sterilnog nosača da se dobije sterilna primarna suspenzija;
subjecting the sterile primary suspension to first pulverization using a high shear pulverizing machine or a dispersion machine that applies shear force to a material to be processed, to form a sterile secondary suspension; and 
podvrgavanje sterilne primarne suspenzije prvom pretvaranju u prah korištenjem stroja za pulverizaciju s visokim smicanjem ili disperzijskog stroja koji primjenjuje silu smicanja na materijal koji se obrađuje, radi dobivanja sterilne sekundarne suspenzije; i
The method according to claim 1 or claim 4, wherein the bulk aripiprazole is in the form selected from the group consisting of monohydrate and Anhydride Crystals B. 
Postupak prema zahtjevu 1 ili zahtjevu 4, naznačen time da je rasuti aripiprazol u obliku koji je odabran iz skupine koju čine monohidrat i anhidridni kristali B.
A method for producing a freeze-dried formulation of Aripiprazole Hydrate A, the method comprising the steps of: cooling the suspension produced by the method according to claim 1 or claim 4 and containing Aripiprazole Hydrate A, to -20 to - 55°C to freeze the suspension; and subsequently performing drying at below about 0°C. 
Postupak za proizvodnju zamrzavanjem osušene formulacije aripiprazol hidrata A, naznačen time da postupak obuhvaća korake: hlađenje suspenzije proizvedene postupkom prema zahtjevu 1 ili zahtjevu 4 i koja sadrži aripiprazol hidrat A, na -20 do - 55°C radi zamrzavanja suspenzije; i nakon toga provođenje sušenja na ispod oko 0°C.
A product according to claim 1 wherein for Compound (I) the pharmaceutically acceptable anion is selected from the group consisting of chloride, bromide, iodide, hydroxide, sulfate, nitrate, phosphate, acetate, trifluoroacetate, fumarate, citrate, tartrate, oxalate, succinate, mandelate, methanesulfonate or p-toluenesulfonate. 
Proizvod namijenjen upotrebi u skladu s patentnim zahtjevom 1, naznačen time što se za Spoj (I) farmaceutski prihvatljiv anion bira iz skupine koju čine klorid, bromid, jodid, hidroksid, sulfat, nitrat, fosfat, acetat, trifluoracetat, fumarat, citrat, tartarat, oksalat, sukcinat, mandelat, metansulfonat ili p-toluensulfonat.
A product according to any of claims 1 to 5, wherein Compound (I) and Compound (II) are presented in a form adapted for separate, sequential or simultaneous administration. 
Proizvod namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 4, naznačen time što su Spoj (I) i Spoj (II) prisutni u obliku prilagođenom za odvojenu, uzastopnu ili istodobnu primjenu.
A product as claimed in any one of claims 1 to 12 wherein Compound (I) is present in an amount of 125 mcg/dose or 62.5 mcg/dose. 
Proizvod namijenjen upotrebi u skladu s bilo kojim od patentnih zahtjeva 1 do 11, naznačen time što je Spoj (I) prisutan u količini od 125 µg po dozi (slobodnog kationa) ili 62,5 µg po dozi (slobodnog kationa).
A compound of Formula IA: 
Spoj formule IA:
The method of claim 43, wherein the disease, disorder, or medical condition is a mood disorder, post-traumatic stress disorder, a panic disorder, an attention deficit disorder, a cognitive deficiency, or substance abuse. 
Spoj za uporabu prema zahtjevu 23, naznačen time da bolest, poremećaj ili medicinsko stanje je poremećaj raspoloženja, posttraumatski poremećaj, panični poremećaj, poremećaj nedostatka pažnje, kognitivna deficijencija ili zloupotreba tvari.
The method of claim 43, wherein the disease, disorder, or medical condition is a sleep disorder. 
Spoj za uporabu prema zahtjevu 23, naznačen time da bolest, poremećaj ili medicinsko stanje je poremećaj spavanja.
The method of claim 43, wherein the disease, disorder, or medical condition is a metabolic disorder. 
Spoj za uporabu prema zahtjevu 23, naznačen time daje bolest, poremećaj ili medicinsko stanje metabolički poremećaj.
The method of claim 47, wherein the metabolic disorder is overweight, obesity, insulin resistance, type II diabetes, hyperlipidemia, gallstones, angina, hypertension, breathlessness, tachycardia, infertility, sleep apnea, back and joint pain, varicose veins, or osteoarthritis. 
Spoj za uporabu prema zahtjevu 27, naznačen time da je metabolički poremećaj prekomjerna težina, gojaznost, otpornost na inzulin, dijabetes tipa II, hiperlipidemija, žučni kamenac, angina, hipertenzija, kratak dah, tahikardija, neplodnost, apneja u snu, bol u leđima i zglobovima, proširene vene, ili osteoartritis.
The method of claim 43, wherein the disease, disorder, or medical condition is a neurological disorder. 
Spoj za uporabu prema zahtjevu 23, naznačen time da je bolest, poremećaj ili medicinsko stanje neurološki poremećaj.
The method of claim 49, wherein the neurological disorder is Parkinson's disease, Alzheimer's disease, Tourette's syndrome, catatonia, anxiety, delirium, or dementias. 
Spoj za uporabu prema zahtjevu 29, naznačen time da je neurološki poremećaj Parkinsonova bolest, Alzheimerova bolest, Touretteov sindrom, katatonija, anksioznost, delirij ili demencija.
The pharmaceutical composition for its use according to claim 3, combined with a compound selected from the group consisting of memantine, amantadine, baclofen, R-baclofen, phenobam, acamprosate, bumetanide, carpipramine, oxytocin, vasopressin and mixtures thereof. 
Farmaceutski pripravak za njegovu upotrebu prema patentnom zahtjevu 3, naznačeno time da je kombiniran sa spojem odabranim iz skupine koju čine memantin, amantadin, baklofen, R-baklofen, fenobam, akamprosat, bumetanid, karpipramin, oksitocin, vazopresin i njihove smjese.
methylthioninium chloride is suspended in an organic solvent with a water content corresponding to a water activity of at least 0.4 at 25°C, the suspension is kept at low temperature, and the solid is isolated and dried to remove the organic solvent and any excess water from the solid; 
metiltioninijklorid se suspendira u organskom otapalu sa sadržajem vode koji odgovara vodenom aktivitetu od najmanje 0,4 na 25°C, a pritom se suspenzija drži na niskoj temperaturi, dok se krutina izolira i suši kako bi se odstranilo organsko otapalo i bilo koji višak vode iz krutine;
methylthioninium chloride is dissolved at elevated temperatures in an organic solvent with a water content corresponding to a water activity of at least 0.4 at 25°C, the solution is cooled, the precipitated solid is isolated and dried to remove the organic solvent and any excess water from the solid; or 
metiltioninijklorid se otapa na povišenim temperaturama u organskom otapalu sa sadržajem vode koji odgovara vodenom aktivitetu od najmanje 0,4 na 25°C, a pritom se otopina hladi, dok se nataložena krutina izolira i suši kako bi se odstranilo organsko otapalo i bilo koji višak vode iz krutine; ili
methylthioninium chloride is dissolved in an organic solvent with a water content corresponding to a water activity of at least 0.4 at 25°C, and the organic solvent and any excess water is evaporated to dryness of the solid 
metiltioninijklorid se otapa u organskom otapalu sa sadržajem vode koji odgovara vodenom aktivitetu od najmanje 0,4 na 25°C, a pritom se organsko otapalo i bilo koji višak vode isparava do suhoće krutine;
wherein drying said methylthioninium chloride pentahydrate Form A to remove excess water and/or solvent is performed by drying in a flow of humid inert gas, wherein the drying conditions are such that the MTC pentahydrate form A is not dehydrated; 
pri čemu se sušenje navedenog metiltioninijklorid (MTC) pentahidrata Oblika A za odstranjivanje viška vode i/ili otapala, provodi putem sušenja u protoku vlažnog inertnog plina, gdje su uvjeti za sušenje takvi, da se MTC pentahidrat Oblika A ne dehidrira;
and wherein the dried methylthioninium chloride pentahydrate Form A has a Form A content of at least 95% based on the total weight of methylthioninium chloride. 
i pritom suhi MTC pentahidrat Oblika A ima sadržaj Oblika A od najmanje 95% na osnovi ukupne mase metiltioninijklorida.
A process according to claim 1, wherein the organic solvent is miscible with water. 
Postupak prema zahtjevu 1, naznačen time, da se organsko otapalo može miješati s vodom.
A process according to any one of claims 1 to 3, wherein the organic solvent used in process variant a) or b) has a dissolving power of less than 20 g/l for methylthioninium chloride pentahydrate form A at room temperature and wherein the organic solvent used in process variant c) has a dissolving power of more than 20 g/l for methylthioninium chloride pentahydrate form A at room temperature. 
Postupak prema bilo kojem od zahtjeva 1 do 3, naznačen time, da organsko otapalo koje se upotrebljava u postupku prema varijanti a) ili b), ima snagu otapanja manju od 20 g/l za metiltioninijklorid pentahidrat Oblika A na sobnoj temperaturi, dok pritom organsko otapalo u postupku prema varijanti c) ima snagu otapanja veću od 20 g/l za metiltioninijklorid pentahidrat Oblika A na sobnoj temperaturi.
A process according to any one of claims 1 to 5, wherein the organic solvent is selected from the group consisting of methanol, ethanol, 1-propanol, 2-propanol, 2-methyl-2-propanol, acetonitrile, tetrahydrofurane, 1,4-dioxane and mixtures thereof. 
Postupak prema bilo kojem od zahtjeva 1 do 5, naznačen time, da se organsko otapalo odabire iz skupine koja se sastoji od metanola, etanola, 1-propanola, -propanola, 2-metil-2-propanola, acetonitrila, tetrahidrofurana, 1,4-dioksana i njihovih mješavina.
A process according to any one of claims 1 to 6, wherein the water content of the liquid phase does not exceed 50% by weight, more preferably 20% by weight, based on the total weight of the liquid phase. 
Postupak prema bilo kojem od zahtjeva 1 do 6, naznačen time, da sadržaj vode u tekućoj fazi ne premašuje 50 masenih %, još bolje 20 masenih %, na osnovi ukupne mase tekuće faze.
A process according to any one of claims 1 to 7, wherein said drying in gas flow is preferably performed at a temperature not higher than 40°C and at a relative humidity of the gas not below 30%. 
Postupak prema bilo kojem od zahtjeva 1 do 7, naznačen time, da se navedeno sušenje u protoku plina poželjno izvodi na temperaturi koja nije viša od 40°C te uz relativnu vlažnost plina koja nije ispod 30%.
A method of drying of MTC pentahydrate Form A to remove excess water and/or solvent by drying in a flow of humid inert gas, wherein the drying conditions are such that the MTC pentahydrate form A is not dehydrated and wherein the dried methylthioninium chloride pentahydrate Form A has a Form A content of at least 95% based on the total weight of methylthioninium chloride. 
Postupak sušenja MTC pentahidrata Oblika A, naznačen time, da služi za odstranjivanje viška vode i/ili otapala putem sušenja u protoku vlažnog inertnog plina, pri čemu su uvjeti sušenja takvi, da MTC pentahidrat Oblika A nije dehidriran i pritom osušeni metiltioninijklorid pentahidrat Oblika A ima sadržaj Oblika A od najmanje 95% na osnovi ukupne mase metiltioninijklorida.
a binding agent; and 
vezivno sredstvo; i
step 1 comprises mixing of dry feed particles with in an arbitrary sequence a dry, cold water soluble, edible and digestible binding agent selected from a group consisting of starch and wheat gluten, and cold liquid such that the binding agent is distributed over the feed particles' surfaces and the amount of liquid is such that the complete mixture contains less than 40% of water by weight; 
korak 1 sadrži miješanje suhih čestica krmiva u proizvoljnom slijedu suhu materiju, u topljivog u hladnoj vodi, jestivog i probavljivog vezivnog sredstva odabran iz skupine koja se sastoji škroba i, pšeničnog glutena i hladnu tekućinu tako da se vezivno sredstvo distribuira preko površina čestica krmiva i količine tekućine je takva da cjelovita smjesa sadrži manje od 40% vode po težini;
step 3 comprises that the feed string formed in step 2 is broken up into suitable pieces by their own weight or are cut with a knife (42). 
korak 3 obuhvaća da je niz krmiva formiran u koraku 2 podijeli u prikladne komade prema vlastitoj težini ili se izreže nožem (42).
Method according to claim 1, characterised in that the wheat gluten consists of vital wheat gluten. 
Postupak sukladno patentnom zahtjevu 1, naznačen time što pšenični gluten sadrži vitalni pšenični gluten.
Method according to claim 1, characterised in that the liquid is selected from the group consisting of fresh water, brackish water, seawater or salt water. 
Postupak sukladno patentnom zahtjevu 1, naznačen time što je ta tekućina odabrana iz skupine koju čini svježa voda, slankasta voda, morska voda ili slana voda.
Method according to claim 1, characterised in that fresh water or seawater constitute said liquid, wheat gluten constitutes said binding agent, and CaCl2 is added to said liquid. 
Postupak sukladno patentnom zahtjevu 1, naznačen time što svježa voda ili morska voda čine navedenu tekućinu, pšenični gluten čini navedeno vezivno sredstvo, i CaCl2 se dodaje u navedenu tekućinu.
at least one binding agent; and 
najmanje jedno vezivno sredstvo; i
Feed block according to claim 5, characterised in that the feed block contains less than 36% of water by weight. 
Blok krmiva sukladno patentnom zahtjevu 5, naznačen time što taj blok sadrži manje od 36% vode po težini.
Feed block according to claim 5, characterised in that the starch is selected from the group consisting of modified potato starch or modified rice starch. 
Blok krmiva sukladno patentnom zahtjevu 5, naznačen time što se taj skrob bira iz grupe koja obuhvata modifikovan krompirov skrob ili modifikovan pirinčani skrob.
Feed block according to claim 5, characterised in that the starch is selected from the group consisting of cereal starch, seed starch, fruit starch, root vegetable starch or marrow starch. 
Blok krmiva sukladno patentnom zahtjevu 5, naznačen time što se taj škrob odabire iz skupine koja sadrži škrob žitarica, škrob sjemenki, voćni škrob, škrob korjena biljke ili škrob koštane srži.
Feed block according to claim 5, characterised in that said wheat gluten consists of vital wheat gluten. 
Blok krmiva sukladno patentnom zahtjevu 5, naznačen time što pšenični gluten sadrži vitalni pšenični gluten.
The compound for the use of claim 56, said method further comprising administering a therapeutically effective amount of at least one additional therapeutic agent, wherein the additional therapeutic agent is selected from the group consisting of cytarabine, bortezomib, and 5-azacitidine. 
Spoj za uporabu prema zahtjevu 56, naznačen time da navedeni postupak nadalje sadrži primjenu terapeutski učinkovite količine najmanje jednog dodatnog terapeutskog sredstva, pri čemu se dodatno terapeutsko sredstvo bira iz skupine koja sadrži citarabin, bortezomib, te 5-azacitidin.
A compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof for use in a method for treating a disease or condition in a subject, said method comprising administering a therapeutically effective amount of a compound of formula (I) according to claim 1 or a pharmaceutically acceptable salt thereof, to a subject in need thereof, wherein said disease or condition is selected from the group consisting of: diabetic nephropathy, hypertensive nephropathy, HIV-associated nephropathy, glomerulonephritis, lupus nephritis, IgA nephropathy, focal segmental glomerulosclerosis, membranous glomerulonephritis, minimal change disease, polycystic kidney disease and tubular interstitial nephritis. 
Spoj s formulom (I) prema zahtjevu 1 ili njegova farmaceutski prihvatljiva sol naznačen time da je za upotrebu u postupku za liječenje bolesti ili stanja kod subjekta, te navedeni postupak sadrži primjenu terapeutski učinkovite količine spoja s formulom (I) prema zahtjevu 1 ili njegove farmaceutski prihvatljive soli, subjektu kojem je to potrebno, pri čemu se navedena bolest ili stanje bira iz skupine koju čine: dijabetička nefropatija, hipertenzijska nefropatija, nefropatija povezana s HIV-om, glomerulonefritis, lupusni nefritis, IgA nefropatija, fokalna segmentna glomeruloskleroza, membranski glomerulonefritis, bolest minimalnih promjena, policistična bolest bubrega i tubularni intersticijski nefritis.